(Q34646752)

3 August 2017

Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. (English)

1 reference

3 August 2017

0 references

1 reference

4

Höglund P

1 reference

3 August 2017

Eriksson T

1

1 reference

PubMed ID

10933131

3 August 2017

Björkman S

series ordinal

2

1 reference

PubMed ID

10933131

3 August 2017

Roth B

series ordinal

3

1 reference

3 August 2017

1 July 2000

1 reference

Journal of Pharmacy and Pharmacology

3 August 2017

1 reference

3 August 2017

52

1 reference

3 August 2017

807-817

1 reference

3 August 2017

7

1 reference

Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide.

3 August 2017

1 reference

https://api.crossref.org/works/10.1211%2F0022357001774660

Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357001774660

The problem of model indistinguishability in pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357001774660

Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357001774660

A double-blind study of the sedative effects of the thalidomide enantiomers in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357001774660

Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357001774660

Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357001774660

Investigations on the in vitro racemization of thalidomide by high-performance liquid chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357001774660

(S)-form of alpha-methyl-N(alpha)-phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-alpha production by human leukemia cell HL-60: implication of optical resolution of thalidomidal effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357001774660

Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357001774660

Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357001774660

Thalidomide: rationale for renewed use in immunological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357001774660

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357001774660

General Treatment of Linear Pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357001774660

21 January 2018

Identifiers

DOI

10.1211/0022357001774660

1 reference

3 August 2017

1 reference

PubMed ID

10933131